UVA1 Phototherapy in Acral Vitiligo

The Role of Long Wavelength UVA1 Phototherapy in Acral Vitiligo

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03378011

Enrollment

Registered

2017-12-19

Start date

2015-11-30

Completion date

2016-11-30

Last updated

2017-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acral Vitiligo

Brief summary

evaluate the effect of UVA1 phototherapy in the treatment of acral vitiligo.

Interventions

OTHERphototherapy

phototherapy either UVA1 or topical PUVA on acral vitiligo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

12 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with acral vitiligo. * Patients more than 12 years old.

Exclusion criteria

* Patients less than 12 years old. * Patients with any other skin diseases or autoimmune diseases. * Patients taking medical treatment or phototherapy for vitiligo.

Design outcomes

Primary

Measure	Time frame	Description
effect of medium dose UVA1 phototherapy in treatment of acral vitiligo	1 year	effect of medium dose UVA1 phototherapy in treatment of acral vitiligo using point counting and vitiligo area severity index (VASI) score

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026